Eli Lilly and Company

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Elanco Animal Health, Ryder System, CytomX, and Hamilton Beach Brands and Encourages Investors to Contact the Firm

Thursday, May 28, 2020 - 12:00am

Elanco Animal Health Incorporated (NYSE: ELAN)

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN)
    Elanco is an animal health company that develops, manufactures, and markets products for companion and food animals.
  • On this news, the Companys share price fell $3.05, or over 13%, to close at $19.88 per share on May 7, 2020.
  • For more information on the Ryder class action go to: https://bespc.com/R
    CytomX operates as an oncology-focused biopharmaceutical company in the U.S.
  • For more information on the Hamilton Beach Brands class action go to: https://bespc.com/HBB
    About Bragar Eagel & Squire, P.C.

Insulin Market Report 2020: Includes Revenue Data (2013-2022) for Novo Nordisk, Sanofi Aventis, Eli Lilly, Merck & Co, and Beckton Dickinson

Wednesday, May 27, 2020 - 4:00pm

According to this report, the global insulin market is estimated to be valued at US$ 60 billion in the year 2025, growing at a CAGR of 8% in the period 2019 to 2025.

Key Points: 
  • According to this report, the global insulin market is estimated to be valued at US$ 60 billion in the year 2025, growing at a CAGR of 8% in the period 2019 to 2025.
  • Growth of the market is driven by factors such as prevalence of diabetes cases, ageing population and growing obese population.
  • It is mainly administered through subcutaneous injection using various insulin delivery devices such as Vials & Syringes, Insulin Pens, Insulin Pumps and Insulin Jet Injectors.
  • This report provides a detailed analysis of the global insulin and insulin delivery devices market from qualitative and quantitative outlooks during the forecast period across various classes.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Elanco Animal Health Incorporated - ELAN

Wednesday, May 27, 2020 - 12:57pm

NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (Elanco or the Company) (NYSE:ELAN).

Key Points: 
  • NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (Elanco or the Company) (NYSE:ELAN).
  • Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
  • On May 7, 2020, Elanco reported its financial and operating results for the first quarter of 2020.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scienti

Wednesday, May 27, 2020 - 12:30pm

Details of the virtual presentations which will provide full clinical study data from that trial follow:

Key Points: 
  • Details of the virtual presentations which will provide full clinical study data from that trial follow:
    Category: 12-F Clinical Therapeutics/New TechnologyOther Therapeutic Agents.
  • Simplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D.
  • The primary endpoint was the change in HbA1c at week 12.The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.
  • Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake.

NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference

Wednesday, May 27, 2020 - 12:00pm

EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference.

Key Points: 
  • EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference.
  • Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
  • Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.
  • Forward-looking statements represent the Companys beliefs and assumptions only as of the date of this press release.

Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

Tuesday, May 26, 2020 - 10:51pm

David A. Ricks, Eli Lilly and Company (NYSE: LLY) Chairman and CEO, attended the announcement at the White House.

Key Points: 
  • David A. Ricks, Eli Lilly and Company (NYSE: LLY) Chairman and CEO, attended the announcement at the White House.
  • This new Part D Senior Savings Model is a natural fit with our other programs that can be found through the Lilly Diabetes Solution Center.
  • We are now able to provide the same opportunity for seniors who enroll in participating Medicare Part D plans.
  • People with questions about the Lilly Insulin Value Program and other solutions offered on Lilly insulins can dial the Lilly Diabetes Solution Center at (833) 808-1234.

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Elanco Animal Health Incorporated (ELAN)

Tuesday, May 26, 2020 - 4:00pm

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of persons and entities that purchased or otherwise acquired Elanco Animal Health Incorporated (Elanco or the Company) (NYSE: ELAN ) securities between January 10, 2020 and May 6, 2020, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of persons and entities that purchased or otherwise acquired Elanco Animal Health Incorporated (Elanco or the Company) (NYSE: ELAN ) securities between January 10, 2020 and May 6, 2020, inclusive (the Class Period).
  • If you purchased or otherwise acquired Elanco securities during the Class Period, you may move the Court no later than July 20, 2020 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Human Growth Hormone May Prevent Loss of Muscle Strength after Anterior Cruciate Ligament Reconstruction

Tuesday, May 26, 2020 - 3:00pm

NEW YORK, May 26, 2020 /PRNewswire/ --Human growth hormone (HGH) may prevent the loss of muscle strength after anterior cruciate ligament (ACL) reconstruction, according to results from a pilot study conducted by investigators at Hospital for Special Surgery (HSS) in collaboration with colleagues at the University of Michigan.

Key Points: 
  • NEW YORK, May 26, 2020 /PRNewswire/ --Human growth hormone (HGH) may prevent the loss of muscle strength after anterior cruciate ligament (ACL) reconstruction, according to results from a pilot study conducted by investigators at Hospital for Special Surgery (HSS) in collaboration with colleagues at the University of Michigan.
  • The drug is available only by prescription for treating growth hormone deficiency syndromes and cannot be used off-label without FDA approval.
  • "We think using human growth hormone to prevent loss of muscle strength after ACL reconstruction would meet the therapeutic use exception guidelines," says Dr. Mendias.
  • "Preventing the loss of strength after ACL reconstruction with human growth hormone may help prevent the development or lessen the severity of osteoarthritis in the future," says Dr. Mendias.

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction

Tuesday, May 26, 2020 - 1:02pm

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction).

Key Points: 
  • Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction).
  • This randomized clinical trial will be conducted, analyzed and reported in partnership with the DCRI, with Boehringer Ingelheim and Lilly providing funding.
  • View the full release here: https://www.businesswire.com/news/home/20200526005445/en/
    EMPACT-MI will include approximately 3,300 adults across at least 16 countries who have had an acute myocardial infarction.
  • The primary endpoint of the trial is to assess the effect of empagliflozin on all-cause mortality and hospitalization for heart failure.

The Law Firm of Barbuto & Johansson, P.A. Announces That a Securities Fraud Class Action Lawsuit Has Been Filed Against Elanco Animal Health Inc.

Tuesday, May 26, 2020 - 8:05am

(with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) advises investors that a Securities Fraud Class Action lawsuit has been filed against Elanco Animal Health, Inc. (NYSE: ELAN), and encourages shareholders with substantial losses to contact the Firm to discuss the case and their options as class members.

Key Points: 
  • (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) advises investors that a Securities Fraud Class Action lawsuit has been filed against Elanco Animal Health, Inc. (NYSE: ELAN), and encourages shareholders with substantial losses to contact the Firm to discuss the case and their options as class members.
  • The case, Sandra Hunter v. Elanco Animal Health Inc., et al., Case No.
  • The lawsuit alleges, in part, that Elanco and certain of its executives failed to disclose material adverse facts about the Companys business during the Class Period, violating federal securities laws.
  • The deadline to petition the court for lead plaintiff is July 20, 2020, so BARJO encourages shareholders with substantial losses to call or write.